Evidence map›Paper›PMID 41097771›Full record

ArticleCancers2025

MicroRNA-379 Modulates Prostate-Specific Antigen Expression Through Targeting the Androgen Receptor in Prostate Cancer.

James R Cassidy, Margareta Persson, Gjendine Voss, Kira Rosenkilde Underbjerg, Tina Catela Ivkovic, Anders Bjartell, Anders Edsjö, Hans Lilja, Yvonne Ceder

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

James R CassidyDivision of Translational Cancer Research, Department of Laboratory Medicine, Lund University, 22381 Lund, Sweden.
Margareta PerssonDivision of Oncology, Department of Clinical Sciences, Lund University, 22381 Lund, Sweden.
Gjendine VossDivision of Translational Cancer Research, Department of Laboratory Medicine, Lund University, 22381 Lund, Sweden.
Kira Rosenkilde UnderbjergDivision of Translational Cancer Research, Department of Laboratory Medicine, Lund University, 22381 Lund, Sweden.
Tina Catela IvkovicDivision of Translational Cancer Research, Department of Laboratory Medicine, Lund University, 22381 Lund, Sweden.
Anders BjartellDepartment of Urology, Skåne University Hospital, 20502 Malmö, Sweden.
Anders EdsjöDepartment of Clinical Genetics and Pathology, Laboratory Medicine, Medical Services, Region Skåne, 22185 Lund, Sweden.
Hans LiljaDepartments of Pathology and Laboratory Medicine, Surgery and Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Yvonne CederDivision of Oncology, Department of Clinical Sciences, Lund University, 22381 Lund, Sweden.ORCID 0000-0002-8705-8293

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
European Union H2020-MSCA-COFUND-2016-74299NCI NIH HHS P30 CA008748Prostatacancerfonden 2022Swedish Cancer Society 22 2346 Pj 01 H
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

metastasesmicroRNAoncogenic and tumor-suppressive miRNAsprostate cancer

Identifiers

PMID41097771
PMCPMC12524244

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.